化合物 (-)-Cevimeline hydrochloride hemihydrate,(-)-Cevimeline hydrochloride hemihydrate

化合物 (-)-Cevimeline hydrochloride hemihydrate|T13421|TargetMol

價(jià)格	￥34800
包裝	25mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-02

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 (-)-Cevimeline hydrochloride hemihydrate	英文名稱:(-)-Cevimeline hydrochloride hemihydrate
品牌: TargetMol	產(chǎn)地: 美國
保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.	產(chǎn)品類別: 抑制劑
貨號(hào): T13421

Product Introduction

Bioactivity

Name	(-)-Cevimeline hydrochloride hemihydrate
Description	Cevimeline hydrochloride hemihydrate ((-)-SNI-2011), a novel muscarinic receptor agonist, is being explored as a potential treatment for xerostomia in Sjogren's syndrome, exhibiting an IC50 value indicative of its affinity for mAChR. This compound's pharmacological effects on the gastrointestinal, urinary, and reproductive systems, alongside its impact on various tissues, were thoroughly examined in species including mice, rats, guinea pigs, rabbits, and dogs. The metabolic breakdown of (-)-SNI-2011 was studied in vitro using rat and dog liver microsomes to assess its biotransformation. Upon oral administration, peak plasma concentrations were reached within an hour in both rats and dogs, showcasing rapid absorption and a subsequent decrease in concentration with a half-life ranging from 0.4 to 1.1 hours. Bioavailability was noted at 50% in rats and 30% in dogs. Metabolic pathways highlighted significant species differences, with both S- and N-oxidized metabolites identified in rats, but only N-oxidized metabolites in dogs. Additionally, gender differences in pharmacokinetics were observed in rats but were absent in dogs. In vitro studies pinpointed the involvement of cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO) in the metabolism of (-)-SNI-2011, specifically through sulfoxidation and N-oxidation processes, respectively. CYP2D and CYP3A were identified as the primary enzymes responsible for sulfoxidation in rat liver microsomes.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Keywords	Cevimeline Hydrochloride \| ( ) Cevimeline hydrochloride hemihydrate \| AF102B Hydrochloride \| SNI2011 \| ()Cevimeline hydrochloride hemihydrate \| SNI 2011 \| AF102B hydrochloride Hemihydrate \| SNI-2011 \| Cevimeline hydrochloride Hemihydrate
Inhibitors Related	Crizotinib \| RepSox \| Ceritinib \| A 83-01 \| Lorlatinib \| ALK-IN-1 \| EML4-ALK kinase inhibitor 1 \| Alectinib hydrochloride \| SB-431542 \| LDN-193189 2HCl \| Brigatinib \| DMH-1

關(guān)鍵字： (-)-SNI-2011|||(-)-AF102B hydrochloride hemihydrate|TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計(jì)算機(jī)輔助藥物設(shè)計(jì)）研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊資本	589.8595萬人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營行業(yè)	中間體,天然產(chǎn)物,生物化工,化學(xué)試劑,生物技術(shù)服務(wù)	經(jīng)營模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 1年

公司成立：12年
注冊資本：589.8595萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：抑制劑&激動(dòng)劑，天然產(chǎn)物，重組蛋白，化合物庫，技術(shù)服務(wù)
公司地址：上海市靜安區(qū)江場三路238號(hào)8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

化合物 RU 752|T26157|TargetMol

￥10600

化合物 VL285 Phenol|T87622|TargetMol

詢價(jià)

化合物 Ormosinine|T70657|TargetMol

￥13800